We discuss the effects of PARP1 chemical inhibition and genetic deficiency on pathological presentations of MS‐modeled animals, point out strengths and weaknesses of available experimental data in the field, and present possible alternative interpretations underlying apparently discrepant findings. Here, PARP1 is linked to myeloid sarcoma.